# Venus Concept Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Venus Concept Inc.). ## Overview Venus Concept Inc. develops and commercializes aesthetic medical devices and related consumables, service contracts, and financing programs for clinics and medical practices. Its portfolio includes systems used for non-invasive and minimally invasive aesthetic procedures, sold across the United States and selected international markets through direct sales, distributors, and internal financing arrangements. ## Products & services • Aesthetic medical systems and consoles • Applicators, handpieces, and procedure kits • Consumables, disposables, and marketing supplies • Extended warranty and service contracts • Venus Prime and legacy subscription financing • ARTAS robotic hair restoration systems - **Aesthetic systems** (55%) — Console-based medical aesthetic devices sold for clinic procedures and treatments. - **Consumables and procedure kits** (15%) — Recurring-use kits, consumables, and disposable items used with installed systems. - **Service and warranty** (10%) — Extended warranty and service contracts provided to existing customers. - **Financing and lease programs** (15%) — Venus Prime and legacy subscription-based arrangements that support system adoption. - **Hair restoration systems** (5%) — ARTAS robotic hair restoration platforms and related procedure products. - Aesthetic medical systems and consoles - Applicators, handpieces, and procedure kits - Consumables, disposables, and marketing supplies - Extended warranty and service contracts - Venus Prime and legacy subscription financing - ARTAS robotic hair restoration systems ## Customers Venus Concept sells primarily to medical aesthetics practices, dermatology and plastic surgery clinics, and other providers that purchase equipment to perform patient procedures. It also serves distributors in certain markets and customers that prefer structured financing or lease-like payment plans to reduce upfront capital needs. - **Medical aesthetics clinics** (primary) — Buy aesthetic systems and consumables to offer non-invasive treatments and recurring patient services. - **Dermatology and plastic surgery practices** (primary) — Purchase platforms and service contracts to expand procedure offerings and patient throughput. - **Financing-oriented customers** (primary) — Use Venus Prime or legacy subscription programs to lower upfront cash outlay for systems. - **Distributors** (secondary) — Buy systems for resale in certain countries where the company uses indirect channels. - **Installed base customers** (secondary) — Purchase consumables, replacement handpieces, and warranty services after initial system sale. - Medical aesthetics clinics buying systems for in-office procedures - Dermatology and plastic surgery practices seeking treatment platforms - Customers using financing to spread equipment payments over time - Distributors that resell systems in selected markets - Existing customers purchasing consumables, kits, and service contracts ## Geography The company sells in the United States and in selected international markets, with direct offices and sales teams in countries where it operates. Management disclosures indicate a stronger focus on the U.S. market, while certain operations, employees, and service providers are located in Israel and the company continues to use distributors in some non-U.S. markets. - United States is the core commercial market for direct sales and financing - Selected international markets are served through direct offices and distributors - North America supports internal lease and Venus Prime financing programs - Israel matters operationally because employees and service providers are located there - Distributor markets add reach but usually carry lower direct economics ## Strategy Venus Concept is prioritizing traditional cash sales over financing-heavy system sales to improve cash generation and reduce credit exposure. It is also concentrating resources on markets where it believes demand and operating economics are more sustainable, while using product breadth and in-house financing to support customer adoption. - **Increase traditional cash sales mix** (short-term) — Reduces working-capital intensity and lowers exposure to customer defaults. - **Expand Venus Prime financing adoption** (medium-term) — Keeps the sales proposition flexible while replacing the legacy subscription model. - **Concentrate on sustainable geographies** (medium-term) — Improves operating efficiency by reducing the burden of underperforming markets. - Shift mix toward traditional cash sales to improve liquidity - Use Venus Prime to preserve financing flexibility for customers - Focus commercial resources on the United States market - Exit countries that do not appear to offer sustainable returns - Broaden the product portfolio to support cross-selling and installed-base revenue ## Risks The business is exposed to customer credit risk, financing risk, and demand sensitivity because a meaningful portion of sales is tied to installment or lease-like programs. It also faces geopolitical, tariff, and supply-chain risks due to operations in Israel and international sourcing and distribution, while product and regulatory execution risks are important in a medical-device business. - **Customer credit and default risk in financing programs** [high] — Venus Prime and legacy subscription sales create long-dated receivables and collection exposure. - **Geopolitical disruption in Israel** [high] — Operations, employees, manufacturers, and consultants are located in Israel. - **Tariffs and customs classification changes** [medium] — Import duties and origin determinations can increase product costs and compliance burden. - **Market demand sensitivity in aesthetic devices** [high] — Clinic purchases depend on discretionary spending, financing availability, and procedure volumes. - **Execution risk on geographic exits and business sales** [medium] — Closing conditions, approvals, and litigation can delay or alter strategic transactions. - Customer defaults can hurt lease-program collections and bad debt expense - International credit tightening can reduce distributor and system demand - Israel exposure creates geopolitical and operational disruption risk - Tariffs and customs rules can raise product costs and reduce competitiveness - Regulatory approvals and customer consents can delay transactions - Medical device quality, warranty, and service obligations can create claims ## Accounting Revenue recognition is judgmental because the company sells systems, consumables, service contracts, and financing arrangements under different accounting models. Long-term receivables, expected credit losses, warranty accruals, and stock-based compensation are also important estimates because they can materially affect reported revenue timing, asset values, and expenses. - **Revenue recognition across multiple sales models** — Affects revenue timing, deferred revenue, and lease-related interest income - **Long-term receivables and expected credit losses** — Affects balance-sheet carrying value and provision expense - **Warranty accruals** — Affects cost of sales and liabilities - **Stock-based compensation** — Affects operating expenses and adjusted EBITDA reconciliation - Revenue is split between ASC 842 lease accounting and ASC 606 product/service sales - Long-term receivables depend on collectability and implicit interest assumptions - Allowance for expected credit losses affects financing-program asset values - Warranty accruals affect service cost estimates and future liabilities - Stock-based compensation and non-recurring items can affect adjusted results --- *Last updated: 2026-04-29T05:07:38.358491+00:00*